



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 



Progesterone Receptor (ZR4)

nordicmubio.com/products/progesterone-receptor-zr4/PR004-G

Catalog number: **PR004-G**

Clone	ZR4
Isotype	IgG
Units	5 ml
Host	Rabbit
Application	Immunohistochemistry (paraffin)

Background

For the evaluation of prognosis and hormone dependency of mamma carcinoma oestrogen and progesterone receptors are determined in the affected tissues. Progesterone receptors are regulated by oestrogens. The antibody to progesterone receptor is well suited to detect the nuclear receptor proteins in appropriate processed tissue sections. For evaluation of prognosis it should always be used in parallel with the determination of oestrogen receptor, EGF receptor, cathepsin D and all relevant clinical factors. Cells and tissues, which are stimulated by the steroid hormone progesterone exhibit specific receptor proteins in their cell nuclei, binding the hormone and transducing the signal. Among these cells are epithelial cells of the uterine myometrium as well as normal and hyperblastic epithelial cells of the breast glands. Human progesterone receptor protein .

Source

Immunogen: Recombinant fragment of human progesterone receptor aa 412-526

Product

Antibody solution in stabilizing phosphate buffer pH 7.3. Contains 0.09 % sodium azide**.

Purification Method: Antibody solution in stabilizing phosphate buffer pH 7.3. Contains 0.09 % sodium azide**.

Specificity

Species Reactivity: Human

Applications

IHC(P)

Incubation Time: 60 min at RT

Working Concentration: (RTU) neat

Pre-Treatment: Pre-treatment using high temperature unmasking methods e.g. with citrate buffer (Art. No. DE000) or TRIS/EDTA (Art.-No. DE006)

Positive Control: Lobular and tubular mamma carcinoma

Storage

2-8°C

Caution

This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals. It may contain hazardous ingredients. Please refer to the Safety Data Sheets (SDS) for additional information and proper handling procedures. Dispose product remainders according to local regulations. This datasheet is as accurate as reasonably achievable, but Exalpha Biologicals accepts no liability for any inaccuracies or omissions in this information.

References

1. Stewart J., King R., Hayward J., et al. (1982) Oestrogen and progesterone receptors: correlation of response rates, sites and timing of analysis. *Breast Cancer Research and Treatment* 2; 243-252. 2.. Clark G.M., McGuire W.L., Hubay C.A. et al. (1983) Progesterone receptors as a prognostic factor in stage II breast cancer. *The New England J. Med.* 309(22); 1343-1347. 3. Giri D.D., Goepel J.R., Rogers K., et al. (1988) Immunohistological demonstration of progesterone receptor in breast carcinomas: correlation with radioligand binding assays and oestrogen receptor immunohistology. *J. Clin. Pathol.* 41; 444-447. 4. Kell D.L., et al. (1993) Immunohistochemical analysis of breast carcinoma estrogen and progesterone receptors in paraffin-embedded tissue: Correlation of clones ER 1D5 and 1A6 with a cytosol-based hormone receptor assay. *Appl. Immunohistochem.* 1(4); 275 ff.

Safety Datasheet(s) for this product:

NM_Sodium Azide